Document is current
Any future updates will be listed below
-
Authors
Lebwohl, Mark G. https://orcid.org/0000-0002-4705-5303
Armstrong, April W. https://orcid.org/0000-0002-6892-6286
Alexis, Andrew F. https://orcid.org/0000-0002-1351-9165
Lain, Edward L. https://orcid.org/0000-0002-0762-1251
Jacobson, Abby A. https://orcid.org/0000-0002-7810-2280
-
Funding
Funding for this research was provided by:
Ortho Dermatologics
- License Information
-
More Information
Article History
Received: 11 June 2024
Accepted: 22 August 2024
First Online: 12 September 2024
Declarations
:
: Mark G. Lebwohl is an employee of Mount Sinai; has received research funding from AbbVie, Amgen, Arcutis Biotherapeutics, Avotres, Boehringer Ingelheim, Cara Therapeutics, Clexio Biosciences, Dermavant Sciences, Incyte, Inozyme, Janssen, Lilly, Ortho Dermatologics (a division of Bausch Health Companies Inc), Pfizer, Sanofi-Regeneron, and UCB; and has served as a consultant for Almirall, AltruBio, AnaptysBio, Apogee, Arcutis Biotherapeutics, AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, Dermsquared, EPI Health, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. April W. Armstrong has served as a research investigator, scientific advisor and/or speaker to AbbVie, Almirall, Arcutis Biotherapeutics, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Dermira, EPI Health, Incyte, Janssen, LEO Pharma, Lilly, Nimbus, Novartis, Ortho Dermatologics (a division of Bausch Health Companies Inc), Pfizer, Sanofi-Regeneron, Sun Pharmaceuticals, and UCB. Andrew F. Alexis has received research funding from AbbVie, Amgen, Arcutis Biotherapeutics, Castle Biosciences, Dermavant Sciences, Galderma, and LEO Pharma; has served as a consultant or advisory board member for AbbVie, Almirall, Allergan, Alphaeon, Alphyn, Amgen, Apogee, Arcutis Biotherapeutics, Bausch Health Companies Inc, Beiersdorf, Bristol-Myers Squibb, Canfield Scientific, Cara Therapeutics, Castle Biosciences, Cutera, Dermavant Sciences, EPI Health, Galderma, Incyte, Janssen, Lilly, L’Oreal, Ortho Dermatologics (a division of Bausch Health Companies Inc), Pfizer, Sanofi-Regeneron, Swiss American, UCB, and VisualDx; has served as a speaker for Bristol-Myers Squibb, Johnson & Johnson, Janssen, L’Oreal, Regeneron, and Sanofi-Genzyme; and has received royalties from Springer, Wiley-Blackwell, and Wolters Kluwer Health and equipment from Aerolase. Edward L. Lain has served as an investigator, speaker, consultant, or advisory board member for AbbVie, Aclaris Therapeutics, AlfaSigma, Allergan, Almirall, Arcutis Biotherapeutics, AstraZeneca, Athenix, Biofrontera, Biopelle, BioPharmX, Biorasi, Brickell Biotech, Bristol-Myers Squibb, Cassiopea S.p.A, Castle Biosciences, Celgene, Cellceutix, ChemoCentryx, Concert Pharma, Cutanea, Dermavant Sciences, Dermira, Dermtech, Dow, Dr. Reddy's Laboratories, Endo Pharma, EPI Health, Evelo, Gage Development Company, Galderma Laboratories, Galderma, Hovione, Incyte, Janssen, Johnson & Johnson, Kadmon Corporation, La Roche-Posay, LEO Pharma, Lilly, MedImmune, Menlo Therapeutics, Mindera, Moleculin, Neothetics, Nielsen Holdings N.V, Novartis, Ortho Dermatologics (a division of Bausch Health Companies Inc), Pierre Fabre, Pfizer, Promius Pharma, Sanofi, Sebacia, Sienna Labs, SkinCeuticals, Sol–Gel Technologies, Sun Pharmaceuticals, Symatese, Timber Pharma, UCB, Valeant Pharmaceuticals North America, and Vyne Therapeutics. Abby A. Jacobson is an employee of Bausch Health Companies Inc.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
